New drug AST-201 targets Hard-to-Treat cancers in first human trial
NCT ID NCT06687941
First seen Apr 09, 2026 · Last updated Apr 26, 2026 · Updated 1 time
Summary
This early-stage study tests a new drug called AST-201 in about 70 adults with advanced solid tumors that have a specific protein called GPC3. The main goal is to check the drug's safety and find the best dose. Researchers will also look at how the drug moves through the body and whether it can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHA Bundang Medical Center
RECRUITINGSeongnam, 13609, South Korea
Contact
-
National Cancer Center, Korea
RECRUITINGGoyang-si, Gyeonggi-do, 10408, South Korea
Contact
Contact
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
Contact
-
Severance Hospital
RECRUITINGSeoul, 03722, South Korea
Contact
Conditions
Explore the condition pages connected to this study.